Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrophosphoric Acid SCHEMBL13738982 | 0.87 | FDPS (0.50) | TSHR | |
| SCHEMBL23037762 | 0.81 | — | — | |
| SCHEMBL39635 | 0.80 | — | — | |
| Phosphoric Acid SCHEMBL27915366 | 0.78 | ACHE (0.38) | TSHRACHENPC1 | |
| SCHEMBL11569436 | 0.77 | — | — | |
| SCHEMBL6790137 | 0.77 | — | — | |
| Lithium SCHEMBL11693507 | 0.77 | — | — | |
| Phosphoric Acid SCHEMBL21437278 | 0.76 | BBOX1 (0.41) | TSHRMAPK1 | |
| Ethylene Glycol SCHEMBL9492826 | 0.75 | ALDH1A1 (0.41) | TSHRNPC1POLBMAPK1HSD17B10 | |
| SCHEMBL6423255 | 0.74 | ACHE (0.39) | TSHRACHENPC1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289662-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LEGOCHEM BIOSCIENCES, INC. (KR) | 2020-09-17 | — | — | US | disclosed |
| US-10583197-B2 | Antibody-active agent conjugates and methods of use | LEGOCHEM BIOSCIENCES, INC. (KR) | 2020-03-10 | — | — | US | disclosed |
| EP-3610889-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | LegoChem Biosciences, Inc. (KR) | 2020-02-19 | — | — | EP | disclosed |
| EP-2707031-B1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | LEGOCHEM BIOSCIENCES INC (KR) | 2019-06-26 | — | — | EP | disclosed |
| US-20180021451-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LIGACHEM BIOSCIENCES INC. (KR) | 2018-01-25 | — | — | US | disclosed |
| US-9669107-B2 | Antibody-active agent conjugates and methods of use | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-06 | — | — | US | disclosed |
| CN-103648530-B | Protein-active agent conjugates and methods of making the same | 乐高化学生物科学股份有限公司 | 2017-02-08 | — | — | CN | disclosed |
| US-20160213786-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LEGOCHEM BIOSCIENCES, INC. (KR) | 2016-07-28 | — | — | US | disclosed |
| US-20150105541-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LIGACHEM BIOSCIENCES INC. (KR) | 2015-04-16 | — | — | US | disclosed |
| US-20140187756-A1 | Methods of preparing antibody-active agent conjugates | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-07-03 | — | — | US | disclosed |
| US-20140161829-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-06-12 | — | — | US | disclosed |
| EP-2707031-A2 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | LegoChem Biosciences, Inc. (KR) | 2014-03-19 | — | — | EP | disclosed |
| CN-103648530-A | Protein-active agent conjugates and methods of making the same | LEGOCHEM BIOSCIENCES INC | 2014-03-19 | — | — | CN | disclosed |
| US-20120308584-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2012-12-06 | — | — | US | disclosed |
| WO-2012153193-A2 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213786-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FNTA, FCGRT, GGT1 | TSHR 3900/4885ACHE 621/4885NPC1 2858/4885 |
| US-20150105541-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FCGRT, CD47, FNTA | TSHR 3065/4885ACHE 2181/4885NPC1 1040/4885 |
| US-20200289662-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FCGRT, CD47, FNTA | TSHR 3065/4885ACHE 2181/4885NPC1 1040/4885 |
| US-10583197-B2 | Antibody-active agent conjugates and methods of use | FNTA, FCGRT, CD47 | TSHR 3204/4885ACHE 1911/4885NPC1 1155/4885 |
| US-20140161829-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FNTA, FCGRT, CD47 | TSHR 3204/4885ACHE 1911/4885NPC1 1155/4885 |
| US-20180021451-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FCGRT, CD47, FNTA | TSHR 3065/4885ACHE 2181/4885NPC1 1040/4885 |
| US-20140187756-A1 | Methods of preparing antibody-active agent conjugates | FNTA, GGT1, ICMT | TSHR 3117/4885ACHE 1291/4885NPC1 2186/4885 |
| US-20120308584-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | FNTA, DNPEP, RCE1 | TSHR 4035/4885ACHE 1730/4885NPC1 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.